Interface of Phospholipase Activity, Immune Cell Function, and Atherosclerosis

Total Page:16

File Type:pdf, Size:1020Kb

Interface of Phospholipase Activity, Immune Cell Function, and Atherosclerosis biomolecules Review Interface of Phospholipase Activity, Immune Cell Function, and Atherosclerosis Robert M. Schilke y, Cassidy M. R. Blackburn y , Temitayo T. Bamgbose and Matthew D. Woolard * Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA; [email protected] (R.M.S.); [email protected] (C.M.R.B.); [email protected] (T.T.B.) * Correspondence: [email protected]; Tel.: +1-(318)-675-4160 These authors contributed equally to this work. y Received: 12 September 2020; Accepted: 13 October 2020; Published: 15 October 2020 Abstract: Phospholipases are a family of lipid-altering enzymes that can either reduce or increase bioactive lipid levels. Bioactive lipids elicit signaling responses, activate transcription factors, promote G-coupled-protein activity, and modulate membrane fluidity, which mediates cellular function. Phospholipases and the bioactive lipids they produce are important regulators of immune cell activity, dictating both pro-inflammatory and pro-resolving activity. During atherosclerosis, pro-inflammatory and pro-resolving activities govern atherosclerosis progression and regression, respectively. This review will look at the interface of phospholipase activity, immune cell function, and atherosclerosis. Keywords: atherosclerosis; phospholipases; macrophages; T cells; lipins 1. Introduction All cellular membranes are composed mostly of phospholipids. Phospholipids are amphiphilic compounds with a hydrophilic, negatively charged phosphate group head and two hydrophobic fatty acid tail residues [1]. The glycerophospholipids, phospholipids with glycerol backbones, are the largest group of phospholipids, which are classified by the modification of the head group [1]. The negatively charged phosphate head forms an ionic bond with an amino alcohol. This bridges the glycerol backbone to the nitrogenous functional group (amino alcohol). The addition of an amino alcohol largely dictates the quaternary structure of the phospholipid [2]. A smaller but also critical family of phospholipids are the sphingolipids, which have sphingosine as a backbone [3]. The amphiphilic make-up of phospholipids allows them to create lipid bilayers, which make cellular membranes and supply structure to cells. Phospholipids also contribute to cellular responses through the binding of receptors, such as lysophosphatidic acid (LPA) binding to the family of LPA receptors, and sphingosine-1-phosphate (S1P) binding to S1P receptors [4]. Components of phospholipids, such as inositol trisphosphate (IP3), diacylglycerol (DAG), and fatty acids, are substrates for the activation of intracellular receptors (e.g., inositol trisphosphate receptors), cofactors for proteins (e.g., protein kinase C), and transcription factors (e.g., peroxisome proliferator-activated receptors (PPARs) [5]. In addition, free fatty acids are also precursors to the prostanoid family of lipid mediators, which can have a broad array of cellular and physiological effects. Phospholipases are a group of enzymes that cleave phospholipids. Each family of phospholipases cleaves a unique site on a phospholipid or unique phospholipid family. Phospholipase A hydrolyzes the fatty acid esters from the sn-1 (PLA1) or sn-2 (PLA2) position of the glycerol backbones, generating free fatty acids [6]. Phospholipase C (PLC) hydrolyzes the glycerol linkage glycerophosphate bond of the polar head, generating DAG and IP3. Phospholipase D (PLD) hydrolyzes the head group of phospholipids, leaving phosphatide and phosphatidic acid (Figure1). Phosphatidic acid phosphatases Biomolecules 2020, 10, 1449; doi:10.3390/biom10101449 www.mdpi.com/journal/biomolecules Biomolecules 2020, 10, x 2 of 18 Biomolecules 2020, 10, 1449 2 of 18 Phosphatidic acid phosphatases are a family of enzymes that can cleave phosphate heads from LPA, PA, and S1P (Figure 1). Phosphatidic acid phosphatases can be split into two families of enzymes, the areLPPs, a family which of cleave enzymes phosphate that can cleave heads phosphate of lipids on heads the from external LPA, side PA, andof the S1P plasma (Figure 1membrane,). Phosphatidic and acidlipins, phosphatases which cleave can PA be intracellularly. split into two families Phospholipases of enzymes, are the critical LPPs, regulators which cleave of phosphatethe liberation heads of ofbioactive lipids oncompounds the external contained side of within the plasma phospholipids membrane, and and subsequent lipins, which physiological cleave PA activity intracellularly. of those Phospholipasescompounds. are critical regulators of the liberation of bioactive compounds contained within phospholipids and subsequent physiological activity of those compounds. Figure 1. Schematic representation of phospholipase enzymatic sites on phospholipids. “X” represents aFigure functional 1. Schematic group. Redrepresentation “O” represents of phospholipase oxygen; orange enzymatic “P” represents sites on phosphorus; phospholipids. grey “X” “C” represents carbon;a functional white group. “H” represents Red “O” hydrogen;represents “R” oxygen; represents orange fatty “P” acid represents tails. Figure phosphorus; Created withgrey BioRender.com“C” represents .carbon; white “H” represents hydrogen; “R” represents fatty acid tails. Figure Created with BioRender.com. Atherosclerosis is an immuno-metabolic disease that leads to myocardial infarction, stroke, or suddenAtherosclerosis death [7]. Excessis an immuno circulating‐metabolic cholesterol disease in the that form leads of low-densityto myocardial lipoproteins infarction, (LDLs) stroke, can or besudden deposited death into [7]. theExcess arterial circulating intima. cholesterol If these LDLs in the are form not quicklyof low‐density removed, lipoproteins they can be (LDLs) modified can (e.g.,be deposited to oxidized into LDL the arterial (oxLDL)) intima. through If these a variety LDLs of are enzymatic not quickly and nonenzymaticremoved, they modifications can be modified [8]. Oxidative(e.g., to oxidized stress LDL is associated (oxLDL)) with through the increaseda variety of oxidation enzymatic of and LDL nonenzymatic and increased modifications atherosclerosis [8]. progression.Oxidative stress Oxidative is associated stress occurs with whenthe increased there is an oxidation imbalance of in LDL the ratioand ofincreased reactive atherosclerosis oxygen species (ROS)progression. and antioxidants Oxidative [stress9,10]. occurs ROS oxidize when thethere polyunsaturated is an imbalance fatty in the acids ratio and of apolipoproteinreactive oxygen B-100 species on the(ROS) LDL and [11 antioxidants,12]. Once formed, [9,10]. oxLDLROS oxidize leads tothe the polyunsaturated recruitment and fatty activation acids and of inflammatory apolipoprotein cells B‐ into100 theon the arterial LDL intima. [11,12]. Monocytes Once formed,/macrophages oxLDL leads are the to mainthe recruitment cells recruited and into activation the intimal of inflammatory space to clear bothcells LDLinto the and arterial oxidized intima. LDL. MacrophagesMonocytes/macrophages engulf LDL (non-oxidized) are the main cells via the recruited low-density into the lipoprotein intimal receptorspace to (LDLR).clear both This LDL initiates and oxidized a negative LDL. feedback Macrophages inhibitory engulf loop LDL resulting (non‐ inoxidized) the downregulation via the low‐ anddensity degradation lipoprotein of thereceptor LDLR. (LDLR). The negative This initiates feedback a negative loop reduces feedback LDL uptakeinhibitory to limitloop intracellularresulting in cholesterol.the downregulation However, and after degradation oxidation, macrophageof the LDLR. scavenger The negative receptors, feedback such loop as CD36, reduces increase LDL uptake oxLDL engulfment,to limit intracellular leading cholesterol. to intracellular However, cholesterol after accumulation oxidation, macrophage and lipid droplet scavenger formation. receptors, such as CD36,A increase broad range oxLDL of immuneengulfment, cells leading and immunological to intracellular mediators cholesterol contribute accumulation to atherosclerosis. and lipid Macrophagesdroplet formation. have long been recognized as a key component of the immune response that determine atherosclerosisA broad range severity of [immune13]. It is nowcells welland establishedimmunological that neutrophils,mediators contribute dendritic cells,to atherosclerosis. T cells, and B cellsMacrophages have important have long cellular been responses recognized within as a key atherosclerotic component plaque of the immune lesions as response well [14 ].that Furthermore, determine immuneatherosclerosis mediators severity such [13]. as pro-inflammatory It is now well established cytokines that (IL-1 neutrophils,β, TNF-α, anddendritic IL-6), cells, anti-inflammatory T cells, and B cytokinescells have (IL-10), important and lipidcellular mediators responses such within as prostaglandins atherosclerotic and plaque pro-resolvins lesions also as contribute.well [14]. Pro-inflammatoryFurthermore, immune macrophage mediators responses, such as pro Th1‐inflammatory and Th17 T cytokines cell responses, (IL‐1β, andTNF the‐α, and cytokines IL‐6), anti and‐ prostaglandinsinflammatory cytokines those cells (IL produce‐10), and promote lipid mediators atherosclerotic such progressionas prostaglandins (Figure and2)[ 15pro,16‐resolvins]. By contrast, also pro-resolvins,contribute. Pro macrophage‐inflammatory efferocytosis, macrophage anti-phospholipid responses, Th1 B cell and responses, Th17 T and cell T regulatoryresponses, celland
Recommended publications
  • ATP-Induced Focal Adhesion Kinase Activity Is Negatively Modulated by Phospholipase D2 in PC12 Cells
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 33, No. 3, 150-155, September 2001 ATP-induced focal adhesion kinase activity is negatively modulated by phospholipase D2 in PC12 cells Yoe-Sik Bae1 and Sung Ho Ryu1,2 Introduction 1 Division of Molecular and Life Sciences, Pohang University of Purinergic receptors have been reported to play impor- Science and Technology, Pohang 790-784, Korea tant roles on the regulation of neuronal cell functions 2 Corresponding author: Tel, +82-54-279-2292; (Communi et al., 2000; Di Iorio et al., 1998). ATP, a Fax, +82-54-279-2199; E-mail, [email protected] ligand for the receptors modulate various cellular re- sponses such as mitogenic and morphogenic activity in Accepted 18 September 2001 PC12 rat pheochromocytoma cells (Neary et al., 1996; Soltoff et al., 1998; Schindelholz et al., 2000). Stimu- Abbreviations: Fak, focal adhesion kinase; PLD, phospholipase D; lation of cells with ATP induces tyrosine phosphorylation PA, phosphatidic acid; PC, phosphatidylcholine; DAG, diacylglyc- of several cytoskeletal proteins and focal adhesion erol; PBt, phosphatidylbutanol; PKC, protein kinase C; PAP, phos- molecules such as focal adhesion kinase (Fak), proline- phatidic acid phosphohydrolase rich tyrosine kinase (Pyk2), and paxillin (Soltoff et al., 1998; Schindelholz et al., 2000). Since these cytosk- eleton-associated proteins have been regarded as important factors for the regulation of neuronal cell Abstract functions, the study on the regulatory mechanism for the proteins remains an important issue. Extracellular ATP has been known to modulate vari- Phospholipase D (PLD) catalyzes the hydrolysis of ous cellular responses including mitogenesis, secre- phosphatidylcholine (PC) into phosphatidic acid (PA) tion and morphogenic activity in neuronal cells.
    [Show full text]
  • Alopecia in a Viable Phospholipase C Delta 1 and Phospholipase C Delta 3 Double Mutant
    Alopecia in a Viable Phospholipase C Delta 1 and Phospholipase C Delta 3 Double Mutant Fabian Runkel1¤, Maik Hintze1,2, Sebastian Griesing1,2, Marion Michels1, Birgit Blanck1, Kiyoko Fukami3, Jean-Louis Gue´net4, Thomas Franz1* 1 Anatomisches Institut, Universita¨t Bonn, Bonn, Germany, 2 Studiengang Molekulare Biomedizin, LIMES, Bonn, Germany, 3 Laboratory of Genome and Biosignal, Tokyo University of Pharmacy and Life Science, Hachioji-city, Tokyo, Japan, 4 De´partement de Biologie du De´veloppement, Institut Pasteur, Paris, France Abstract Background: Inositol 1,4,5trisphosphate (IP3) and diacylglycerol (DAG) are important intracellular signalling molecules in various tissues. They are generated by the phospholipase C family of enzymes, of which phospholipase C delta (PLCD) forms one class. Studies with functional inactivation of Plcd isozyme encoding genes in mice have revealed that loss of both Plcd1 and Plcd3 causes early embryonic death. Inactivation of Plcd1 alone causes loss of hair (alopecia), whereas inactivation of Plcd3 alone has no apparent phenotypic effect. To investigate a possible synergy of Plcd1 and Plcd3 in postnatal mice, novel mutations of these genes compatible with life after birth need to be found. Methodology/Principal Findings: We characterise a novel mouse mutant with a spontaneously arisen mutation in Plcd3 (Plcd3mNab) that resulted from the insertion of an intracisternal A particle (IAP) into intron 2 of the Plcd3 gene. This mutation leads to the predominant expression of a truncated PLCD3 protein lacking the N-terminal PH domain. C3H mice that carry one or two mutant Plcd3mNab alleles are phenotypically normal. However, the presence of one Plcd3mNab allele exacerbates the alopecia caused by the loss of functional Plcd1 in Del(9)olt1Pas mutant mice with respect to the number of hair follicles affected and the body region involved.
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Inhibitory Effects of Plant Phenolic Compounds on Enzymatic and Cytotoxic Activities Induced by a Snake Venom Phospholipase A
    295 VITAE, REVISTA DE LA FACULTAD DE QUÍMICA FARMACÉUTICA ISSN 0121-4004 / ISSNe 2145-2660. Volumen 18 número 3, año 2011. Universidad de Antioquia, Medellín, Colombia. págs. 295-304 INHIBITORY EFFECTS OF PLANT PHENOLIC COMPOUNDS ON ENZYMATIC AND CYTOTOXIC ACTIVITIES INDUCED BY A SNAKE VENOM PHOSPHOLIPASE A 2 EFECTOS INHIBITORIOS DE COMPUESTOS FENÓLICOS DE PLANTAS SOBRE LA ACTIVIDAD ENZIMÁTICA Y CITOTOXICA INDUCIDA POR UNA FOSFOLIPASA A 2 DE VENENO DE SERPIENTE Jaime A. PEREAÑEZ 1*, Vitelbina NÚÑEZ 1,2 , Arley C. PATIÑO 1, Mónica LONDOÑO 1, Juan C. QUINTANA 1 Received: 23 February 2010 Accepted: 25 April 2011 ABSTRACT Polyphenolic compounds have shown to inhibit toxic effects induced by snake venom proteins. In this work, we demonstrate that gallic acid, ferulic acid, caffeic acid, propylgallate and epigallocatechingallate inhibit the enzymatic activity of a phospholipase A 2 (PLA 2), using egg yolk as substrate. The IC50 values are between 0.38 – 3.93 mM. These polyphenolic compounds also inhibit the PLA 2 enzymatic activity when synthetic substrate is used. Furthermore, these compounds decreased the cyotoxic effect induced by a myotoxic PLA 2; specifically, epigallocatechin gallate exhibited the best inhibitory capacity with 90.92 ± 0.82%, while ferulic acid showed the lowest inhibitory activity with 30.96 ± 1.42%. Molecular docking studies were performed in order to determine the possible modes of action of phenolic compounds. All polyphenols showed hydrogen bonds with an active site of enzyme; moreover, epigallocatechingallate presented the strongest binding compared with the other compounds. Additionally, a preliminary structure-activity relationship analysis showed a correlation between the IC50 and the topological polar surface area of each compound (p = 0.0491, r = -0.8079 (-0.9878 to -0.2593)), which indicates the surface area required for each molecule to bind with the majority of the enzyme.
    [Show full text]
  • Increased O-Glcnacylation Rapidly Decreases GABAAR Currents in Hippocampus but Depresses Neuronal Output L
    www.nature.com/scientificreports OPEN Increased O-GlcNAcylation rapidly decreases GABAAR currents in hippocampus but depresses neuronal output L. T. Stewart1,3, K. Abiraman1,3, J. C. Chatham2 & L. L. McMahon1 ✉ O-GlcNAcylation, a post-translational modifcation involving O-linkage of β-N-acetylglucosamine to Ser/Thr residues on target proteins, is increasingly recognized as a critical regulator of synaptic function. Enzymes that catalyze O-GlcNAcylation are found at both presynaptic and postsynaptic sites, and O-GlcNAcylated proteins localize to synaptosomes. An acute increase in O-GlcNAcylation can afect neuronal communication by inducing long-term depression (LTD) of excitatory transmission at hippocampal CA3-CA1 synapses, as well as suppressing hyperexcitable circuits in vitro and in vivo. Despite these fndings, to date, no studies have directly examined how O-GlcNAcylation modulates the efcacy of inhibitory neurotransmission. Here we show an acute increase in O-GlcNAc dampens GABAergic currents onto principal cells in rodent hippocampus likely through a postsynaptic mechanism, and has a variable efect on the excitation/inhibition balance. The overall efect of increased O-GlcNAc is reduced synaptically-driven spike probability via synaptic depression and decreased intrinsic excitability. Our results position O-GlcNAcylation as a novel regulator of the overall excitation/inhibition balance and neuronal output. Synaptic integration and spike initiation in neurons is controlled by synaptic inhibition, which strongly infu- ences neuronal output and information processing1. Importantly, the balance of excitation to inhibition (E/I) is crucial to the proper functioning of circuits, and E/I imbalances have been implicated in a number of neurode- velopmental disorders and neurodegenerative diseases including schizophrenia, autism spectrum disorders, and Alzheimer’s disease2–5.
    [Show full text]
  • Circulating Supar in Two Cohorts of Primary FSGS
    CLINICAL RESEARCH www.jasn.org Circulating suPAR in Two Cohorts of Primary FSGS † ‡ Changli Wei,* Howard Trachtman, Jing Li,* Chuanhui Dong, Aaron L. Friedman,§ | | | Jennifer J. Gassman, June L. McMahan, Milena Radeva, Karsten M. Heil,¶ †† ‡‡ Agnes Trautmann,¶ Ali Anarat,** Sevinc Emre, Gian M. Ghiggeri, Fatih Ozaltin,§§ || ††† Dieter Haffner, Debbie S. Gipson,¶¶ Frederick Kaskel,*** Dagmar-Christiane Fischer, ‡‡‡ Franz Schaefer,¶ and Jochen Reiser, for the PodoNet and FSGS CT Study Consortia Departments of *Medicine and ‡Neurology, University of Miami Miller School of Medicine, Miami, Florida; †Department of Pediatrics, NYU Langone Medical Center, New York, New York; §Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; |Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; ¶Center for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany; **Department of Pediatric Nephrology, Cukurova University School of Medicine, Adana, Turkey; ††Department of Pediatrics, Istanbul Medical Faculty, University of Istanbul, Istanbul, Turkey; ‡‡Division of Nephrology, Dialysis, and Transplantation, Laboratory on Pathophysiology of Uremia, G. Gaslini Children’s Hospital, Genoa, Italy; §§Pediatric Nephrology Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey; ||Department of Pediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany; ¶¶Department of Pediatrics, University of Michigan, Ann Arbor, Michigan; ***Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York; †††Department of Pediatrics, Rostock University Hospital, Rostock, Germany; and ‡‡‡Department of Medicine, Rush University Medical Center, Chicago, Illinois ABSTRACT Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to pri- mary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease.
    [Show full text]
  • Lysophosphatidic Acid and Its Receptors: Pharmacology and Therapeutic Potential in Atherosclerosis and Vascular Disease
    JPT-107404; No of Pages 13 Pharmacology & Therapeutics xxx (2019) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease Ying Zhou a, Peter J. Little a,b, Hang T. Ta a,c, Suowen Xu d, Danielle Kamato a,b,⁎ a School of Pharmacy, University of Queensland, Pharmacy Australia Centre of Excellence, Woolloongabba, QLD 4102, Australia b Department of Pharmacy, Xinhua College of Sun Yat-sen University, Tianhe District, Guangzhou 510520, China c Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, St Lucia, QLD 4072, Australia d Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA article info abstract Available online xxxx Lysophosphatidic acid (LPA) is a collective name for a set of bioactive lipid species. Via six widely distributed G protein-coupled receptors (GPCRs), LPA elicits a plethora of biological responses, contributing to inflammation, Keywords: thrombosis and atherosclerosis. There have recently been considerable advances in GPCR signaling especially Lysophosphatidic acid recognition of the extended role for GPCR transactivation of tyrosine and serine/threonine kinase growth factor G-protein coupled receptors receptors. This review covers LPA signaling pathways in the light of new information. The use of transgenic and Atherosclerosis gene knockout animals, gene manipulated cells, pharmacological LPA receptor agonists and antagonists have Gproteins fi β-arrestins provided many insights into the biological signi cance of LPA and individual LPA receptors in the progression Transactivation of atherosclerosis and vascular diseases.
    [Show full text]
  • PLCG1) Mutations in Sézary Syndrome
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Functional interrogations of Phospholipase C Gamma 1 (PLCG1) mutations in Sézary Syndrome Patel, Varsha Maheshkumar Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 11. Oct. 2021 Functional interrogations of Phospholipase C Gamma 1 (PLCG1) mutations in Sézary Syndrome Varsha Maheshkumar Patel Skin Tumour Unit, St John’s Institute of Dermatology, School of Basic and Medical Biosciences, King’s College London.
    [Show full text]
  • Identification and Dynamics of the Human ZDHHC16-ZDHHC6 Palmitoylation Cascade
    RESEARCH ARTICLE Identification and dynamics of the human ZDHHC16-ZDHHC6 palmitoylation cascade Laurence Abrami1†, Tiziano Dallavilla1,2†, Patrick A Sandoz1, Mustafa Demir1, Be´ atrice Kunz1, Georgios Savoglidis2, Vassily Hatzimanikatis2*, F Gisou van der Goot1* 1Global Health Institute, Faculty of Life Sciences, Ecole Polytechnique Fe´de´rale de Lausanne, Lausanne, Switzerland; 2Laboratory of Computational Systems Biotechnology, Faculty of Basic Sciences, Ecole Polytechnique Fe´de´rale de Lausanne, Lausanne, Switzerland Abstract S-Palmitoylation is the only reversible post-translational lipid modification. Knowledge about the DHHC palmitoyltransferase family is still limited. Here we show that human ZDHHC6, which modifies key proteins of the endoplasmic reticulum, is controlled by an upstream palmitoyltransferase, ZDHHC16, revealing the first palmitoylation cascade. The combination of site specific mutagenesis of the three ZDHHC6 palmitoylation sites, experimental determination of kinetic parameters and data-driven mathematical modelling allowed us to obtain detailed information on the eight differentially palmitoylated ZDHHC6 species. We found that species rapidly interconvert through the action of ZDHHC16 and the Acyl Protein Thioesterase APT2, that each species varies in terms of turnover rate and activity, altogether allowing the cell to robustly *For correspondence: tune its ZDHHC6 activity. [email protected] DOI: https://doi.org/10.7554/eLife.27826.001 (VH); [email protected] (FGG) †These authors contributed equally to this work Introduction Cells constantly interact with and respond to their environment. This requires tight control of protein Competing interests: The function in time and in space, which largely occurs through reversible post-translational modifica- authors declare that no tions of proteins, such as phosphorylation, ubiquitination and S-palmitoylation.
    [Show full text]
  • (4,5) Bisphosphate-Phospholipase C Resynthesis Cycle: Pitps Bridge the ER-PM GAP
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Topological organisation of the phosphatidylinositol (4,5) bisphosphate-phospholipase C resynthesis cycle: PITPs bridge the ER-PM GAP Shamshad Cockcroft and Padinjat Raghu* Dept. of Neuroscience, Physiology and Pharmacology, Division of Biosciences, University College London, London WC1E 6JJ, UK; *National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India Address correspondence to: Shamshad Cockcroft, University College London UK; Phone: 0044-20-7679-6259; Email: [email protected] Abstract Phospholipase C (PLC) is a receptor-regulated enzyme that hydrolyses phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) at the plasma membrane (PM) triggering three biochemical consequences, the generation of soluble inositol 1,4,5-trisphosphate (IP3), membrane– associated diacylglycerol (DG) and the consumption of plasma membrane PI(4,5)P2. Each of these three signals triggers multiple molecular processes impacting key cellular properties. The activation of PLC also triggers a sequence of biochemical reactions, collectively referred to as the PI(4,5)P2 cycle that culminates in the resynthesis of this lipid. The biochemical intermediates of this cycle and the enzymes that mediate these reactions are topologically distributed across two membrane compartments, the PM and the endoplasmic reticulum (ER). At the plasma membrane, the DG formed during PLC activation is rapidly converted to phosphatidic acid (PA) that needs to be transported to the ER where the machinery for its conversion into PI is localised. Conversely, PI from the ER needs to be rapidly transferred to the plasma membrane where it can be phosphorylated by lipid kinases to regenerate PI(4,5)P2.
    [Show full text]
  • Role of Phospholipases in Adrenal Steroidogenesis
    229 1 W B BOLLAG Phospholipases in adrenal 229:1 R29–R41 Review steroidogenesis Role of phospholipases in adrenal steroidogenesis Wendy B Bollag Correspondence should be addressed Charlie Norwood VA Medical Center, One Freedom Way, Augusta, GA, USA to W B Bollag Department of Physiology, Medical College of Georgia, Augusta University (formerly Georgia Regents Email University), Augusta, GA, USA [email protected] Abstract Phospholipases are lipid-metabolizing enzymes that hydrolyze phospholipids. In some Key Words cases, their activity results in remodeling of lipids and/or allows the synthesis of other f adrenal cortex lipids. In other cases, however, and of interest to the topic of adrenal steroidogenesis, f angiotensin phospholipases produce second messengers that modify the function of a cell. In this f intracellular signaling review, the enzymatic reactions, products, and effectors of three phospholipases, f phospholipids phospholipase C, phospholipase D, and phospholipase A2, are discussed. Although f signal transduction much data have been obtained concerning the role of phospholipases C and D in regulating adrenal steroid hormone production, there are still many gaps in our knowledge. Furthermore, little is known about the involvement of phospholipase A2, Endocrinology perhaps, in part, because this enzyme comprises a large family of related enzymes of that are differentially regulated and with different functions. This review presents the evidence supporting the role of each of these phospholipases in steroidogenesis in the Journal Journal of Endocrinology adrenal cortex. (2016) 229, R1–R13 Introduction associated GTP-binding protein exchanges a bound GDP for a GTP. The G protein with GTP bound can then Phospholipids serve a structural function in the cell in that activate the enzyme, phospholipase C (PLC), that cleaves they form the lipid bilayer that maintains cell integrity.
    [Show full text]
  • Phospholipase C-Related Catalytically Inactive Protein: a Novel Signaling Molecule for Modulating Fat Metabolism and Energy Expenditure
    Journal of Oral Biosciences 61 (2019) 65e72 Contents lists available at ScienceDirect Journal of Oral Biosciences journal homepage: www.elsevier.com/locate/job Review Phospholipase C-related catalytically inactive protein: A novel signaling molecule for modulating fat metabolism and energy expenditure * Takashi Kanematsu a, b, , Kana Oue a, c, Toshiya Okumura a, Kae Harada a, 1, Yosuke Yamawaki a, 2, Satoshi Asano a, Akiko Mizokami d, Masahiro Irifune c, Masato Hirata e a Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan b Department of Cell Biology and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan c Department of Dental Anesthesiology, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734- 8553, Japan d OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan e Fukuoka Dental College, Fukuoka, 814-0193, Japan article info abstract Article history: Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose Received 16 March 2019 tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 Received in revised form diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong 17 April 2019 evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and Accepted 19 April 2019 improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and Available online 15 May 2019 high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti- obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been Keywords: Adipose tissue developed.
    [Show full text]